Next year, I will give one of my SpaceX shares to every kid in America. This will be the first of many.

of course that's your contention. you're a first-year frontier bio guy. you just finished reading about CRISPR, probably watched a Doudna talk too. so now you're convinced everything is just gene editing. that's gonna last until next month when you discover base editing, and then you're gonna be talkin' about how cutting DNA was barbaric and double-strand breaks are a legacy approach. then you're gonna read about delivery, and suddenly everything's about lipid nanoparticles and how editing was the easy part and the whole goddamn thing is bottlenecked by getting it to the right organ. that'll last until somebody shows you AlphaFold, and then you're gonna be in here regurgitating DeepMind, talkin' about de novo enzymes and virtual cells and how wet labs are economically obsolete. then six months from now you'll watch one assay fail four times in a real lab, and start telling everybody the bottleneck was never ideas, it's validation. somewhere in there you'll find a guy named Keith on Telegram, and you'll start doing reconstitution math in your head at dinner. and by next year you're gonna be standing right here explaining to me you reversed your biological age by six years because you picked the clock that said so.

Not sure a speculative biotech investor needs more than $PRME and $ARWR at this point. BOTH will be monsters long term imo I’m simplifying.

Upon closing, the combined company is expected to be the only U.S. publicly listed pure-play humanoid robotics company with proven, active commercial deployments.